BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12820333)

  • 21. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
    Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
    Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
    Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
    Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K
    BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
    Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
    Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
    Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
    Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
    Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
    Stephan C; Jung K; Soosaipillai A; Yousef GM; Cammann H; Meyer H; Xu C; Diamandis EP
    BJU Int; 2005 Sep; 96(4):521-7. PubMed ID: 16104903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics.
    Jung K; Lein M; Butz H; Stephan C; Loening SA; Keller T
    J Urol; 2006 Apr; 175(4):1275-80. PubMed ID: 16515979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate.
    Kapoor N; Jain R; Surange S; Bhardwaj VK; Srivastava A
    Indian J Pathol Microbiol; 2006 Apr; 49(2):178-81. PubMed ID: 16933710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
    Miller MC; O'Dowd GJ; Partin AW; Veltri RW
    Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients.
    Battikhi MN
    Prostate Cancer Prostatic Dis; 2003; 6(3):256-60. PubMed ID: 12970732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW; Liu G; Sheng BW
    Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Parameters of PSA fractions in early diagnosis of prostatic cancer in healthy males over 50].
    Loran OB; Krokhotina LV; Pushkar' DIu; Valiev AZ; Rasner PI
    Urol Nefrol (Mosk); 1999; (1):19-21. PubMed ID: 11149339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The detection and potential economic value of complexed prostate specific antigen as a first line test.
    Babaian RJ; Naya Y; Cheli C; Fritsche HA
    J Urol; 2006 Mar; 175(3 Pt 1):897-901; discussion 901. PubMed ID: 16469574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of prostate manipulation on the serum levels of complexed prostate-specific antigen and total prostate-specific antigen.
    Long R; Giri S; Diver S; Duddy L; McKeown D; Moran K
    Int J Urol; 2006 Jul; 13(7):947-50. PubMed ID: 16882060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.